Send us a text

Discover the latest breakthroughs from ASCO 2024 with The Oncology Journal Club team!

Professor Chris Jackson, who, despite battling the infamous man flu, brings his A-game to dissect the NADINA study. Learn how neoadjuvant ipilimumab and nivolumab are transforming resectable stage 3 melanoma treatment with a remarkable 26 percentage point gain in 12-month event-free survival. Chris shines a spotlight on the innovative design of this trial and its promising implications for reducing treatment duration and financial strain.

But that's just the beginning. Dive into the long-term data from the COMBI-AD study, where we explore the enduring effects of dabrafenib and trametinib on melanoma patients with V600 mutations. We’ll unpack the nuances between V600E and V600K mutations and discuss how these findings could shift clinical practice towards more effective strategies. Plus, Dr Kate Clarke talks us through the latest on the A-BRAVE study in triple-negative breast cancer and its quest for improved disease-free survival rates.

And of course our Host Professor Craig Underhill unpacks the incredible paradigm-shifting data in  lung cancer that could redefine clinical protocols. He also explores the expanding frontier of telehealth in palliative care and its game-changing potential, especially for remote communities.

Covering a whopping 17 abstracts, this second ASCO 2024 Special Episode is packed with critical insights and forward-thinking discussions that no oncology professional should miss. Join us for a thought-provoking and entertaining journey through the latest in cancer research and care.

For papers, bios and other links visit the Show Notes on our website.

For the latest oncology news visit www.oncologynews.com.au.

We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.